icatibant accord
accord healthcare s.l.u. - icatibant acetate - angioødemer, arvelige - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.
icatibant "newbury" 30 mg injektionsvæske, opløsning i fyldt injektionssprøjte
newbury pharmaceuticals ab - icatibant - injektionsvæske, opløsning i fyldt injektionssprøjte - 30 mg
ciclosporin "actavis" 100 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 100 mg
ciclosporin "actavis" 25 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 25 mg
ciclosporin "actavis" 50 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 50 mg
icatibant "aguettant" 30 mg injektionsvæske, opløsning i fyldt injektionssprøjte
laboratoire aguettant - icatibant - injektionsvæske, opløsning i fyldt injektionssprøjte - 30 mg
icatibant "sun" 30 mg injektionsvæske, opløsning i fyldt injektionssprøjte
sun pharmaceutical industries europe bv - icatibant - injektionsvæske, opløsning i fyldt injektionssprøjte - 30 mg
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - medicin for obstruktiv sygdomme, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - medicin for obstruktiv sygdomme, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - medicin for obstruktiv sygdomme, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.